Key Events This Week
09 Feb: Stock opens at ₹863.90, up 2.48% from previous week
10 Feb: MarketsMOJO upgrades rating to Hold on improved technicals and valuation
12 Feb: Technical momentum shifts from mildly bullish to sideways trend
13 Feb: Technical momentum shifts back to mildly bullish amid mixed signals
Monday, 09 February 2026: Strong Opening with Sensex Support
Strides Pharma began the week on a positive note, closing at ₹885.30, a gain of 2.48% from the previous Friday’s close of ₹863.90. This outperformance was in line with the Sensex’s 1.04% rise to 37,113.23, reflecting broader market optimism. The stock’s volume was moderate at 7,683 shares, indicating steady investor interest. This strong start set the tone for the week, positioning the stock near its recent highs.
Tuesday, 10 February 2026: Rating Upgrade Spurs Mild Bullish Momentum
On 10 February, Strides Pharma’s rating was upgraded from Sell to Hold by MarketsMOJO, citing improved technical indicators and attractive valuation metrics. The stock closed slightly lower at ₹884.20, down 0.12%, despite the positive news. The upgrade reflected a shift in technical momentum to mildly bullish, supported by daily moving averages and a more favourable price-to-earnings ratio of 14.72 compared to sector peers. The Sensex also advanced 0.25% to 37,207.34, providing a supportive backdrop.
Fresh entry alert! This Small Cap from Electronics & Appliances sector is already turning heads in our Top 1% club. Get ahead of the market now!
- - New Top 1% entry
- - Market attention building
- - Early positioning opportunity
Wednesday, 11 February 2026: Decline Amid Mixed Technical Signals
The stock experienced a sharper decline on 11 February, closing at ₹877.60, down 0.75%. This drop contrasted with the Sensex’s modest 0.13% gain to 37,256.72, signalling relative weakness. Technical indicators such as MACD and KST remained mildly bearish on weekly and monthly charts, suggesting waning momentum despite the recent upgrade. The Relative Strength Index (RSI) remained neutral, indicating no immediate overbought or oversold conditions. Volume was lower at 4,651 shares, reflecting reduced trading interest amid uncertainty.
Thursday, 12 February 2026: Momentum Shifts to Sideways as Caution Prevails
On 12 February, Strides Pharma’s technical momentum shifted from mildly bullish to a sideways trend, closing at ₹865.60, down 1.37%. The Sensex declined 0.56% to 37,049.40, indicating a broader market pullback. Mixed signals from technical indicators persisted: the MACD and KST oscillators remained mildly bearish, while daily moving averages stayed mildly bullish. Bollinger Bands suggested a mildly bearish weekly outlook but a mildly bullish monthly trend, highlighting the stock’s indecision. Volume dropped further to 3,264 shares, underscoring investor caution.
Friday, 13 February 2026: Mildly Bullish Momentum Returns Amid Mixed Signals
Strides Pharma closed the week at ₹857.35, down 0.95% on the day, as technical momentum shifted back to mildly bullish from sideways. The Sensex fell 1.40% to 36,532.48, marking a more pronounced market decline. Daily moving averages turned mildly bullish, supported by a mildly bullish weekly On-Balance Volume (OBV) trend, suggesting some volume backing for recent gains. However, MACD and KST indicators remained cautiously bearish on weekly and monthly charts, and the monthly RSI stayed bearish. This combination points to tentative optimism tempered by longer-term caution.
Holding Strides Pharma Science Ltd from ? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-02-09 | Rs.885.30 | +2.48% | 37,113.23 | +1.04% |
| 2026-02-10 | Rs.884.20 | -0.12% | 37,207.34 | +0.25% |
| 2026-02-11 | Rs.877.60 | -0.75% | 37,256.72 | +0.13% |
| 2026-02-12 | Rs.865.60 | -1.37% | 37,049.40 | -0.56% |
| 2026-02-13 | Rs.857.35 | -0.95% | 36,532.48 | -1.40% |
Key Takeaways
The week’s price action and technical developments for Strides Pharma Science Ltd reveal a complex interplay of factors. The MarketsMOJO upgrade to Hold on 10 February was a significant positive, reflecting improved valuation metrics such as a PE ratio of 14.72 and a robust quarterly profit growth of 133.64%. However, the stock’s inability to sustain gains and the subsequent shift in technical momentum to sideways and then mildly bullish highlight ongoing uncertainty.
Technical indicators present a mixed picture: while daily moving averages suggest short-term bullishness, momentum oscillators like MACD and KST remain mildly bearish on weekly and monthly charts. The RSI’s neutral to bearish stance and lack of strong volume confirmation further temper enthusiasm. The stock’s relative underperformance versus the Sensex in the latter half of the week (-0.76% vs -0.54%) underscores this cautious environment.
Long-term fundamentals remain strong, with Strides Pharma delivering exceptional returns over three and five years, vastly outperforming the Sensex. Yet, near-term volatility and elevated promoter share pledging at 30.6% introduce risk factors that investors should monitor closely. The company’s debt servicing capacity, with a debt-to-EBITDA ratio of 6.58 times, also warrants attention amid fluctuating earnings.
Overall, the week’s developments suggest a stock at a technical crossroads, balancing improved valuation and financial performance against mixed momentum signals and market caution.
Unlock special upgrade rates for a limited period. Start Saving Now →
Conclusion
Strides Pharma Science Ltd’s week ended with a modest decline of 0.76%, slightly underperforming the Sensex’s 0.54% fall. The MarketsMOJO upgrade to Hold on 10 February marked a pivotal moment, recognising improved technical and valuation factors amid strong quarterly earnings. However, the subsequent shifts in technical momentum from mildly bullish to sideways and back to mildly bullish, combined with mixed indicator signals, suggest a cautious near-term outlook.
Investors should remain attentive to key technical levels around ₹870 and monitor momentum oscillators for clearer directional cues. The stock’s strong long-term performance relative to the Sensex and pharmaceutical peers remains a positive backdrop, but near-term volatility and fundamental risks such as promoter pledging and debt levels require careful consideration. The Hold rating encapsulates this balanced view, signalling neither a strong buy nor a sell stance but a watchful approach as the stock navigates its current technical phase.
